Cynosure designs, manufactures and markets medical devices for aesthetic procedures and precision surgical applications worldwide. The Company’s products enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, liquefy and remove unwanted fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve vaginal health. Cynosure also markets radiofrequency energy sourced medical devices for precision surgical applications such as facial plastic and general surgery, gynecology, ear, nose, and throat procedures, ophthalmology, oral and maxillofacial surgery, podiatry and proctology. Cynosure's product portfolio is composed of a broad range of energy sources including Alexandrite, diode, Nd: YAG, picosecond, pulse dye, Q-switched lasers, intense pulsed light and radiofrequency technology. Cynosure sells its products globally under the Cynosure, Palomar, ConBio and Ellman brand names through a direct sales force in the United States, Canada, Mexico, France, Germany, Spain, the United Kingdom, Australia, China, Japan and Korea, and through international distributors in approximately 120 other countries.

CYNO (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$51.60
Change (%) Stock is Up 0.52 (1.02%)
Volume57,751
Data as of 08/29/16 12:06 p.m. ET
Minimum 20 minute delay
Refresh quote

News Releases

July 26, 2016
Cynosure Reports Net Income of $6.3 Million on Record Sales of $110.3 Million for the Second Quarter of 2016
July 26, 2016
Cynosure Receives Approval to Market SculpSure® in South Korea
July 14, 2016
Cynosure To Host Second-Quarter 2016 Financial Results Conference Call On July 26
View All Press Releases

Upcoming Events

There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed.